$-0.45 EPS Expected for Entellus Medical, Inc. (ENTL); Icc Holdings (ICCH) SI Increased By 176.67%

February 6, 2018 - By Stephen Andrade

Analysts expect Entellus Medical, Inc. (NASDAQ:ENTL) to report $-0.45 EPS on February, 20.They anticipate $0.06 EPS change or 15.38% from last quarter’s $-0.39 EPS. After having $-0.49 EPS previously, Entellus Medical, Inc.’s analysts see -8.16% EPS growth. The stock decreased 0.42% or $0.1 during the last trading session, reaching $23.99. About 123,695 shares traded. Entellus Medical, Inc. (NASDAQ:ENTL) has declined 17.59% since February 6, 2017 and is downtrending. It has underperformed by 34.29% the S&P500.

Icc Holdings Incorporated (NASDAQ:ICCH) had an increase of 176.67% in short interest. ICCH’s SI was 8,300 shares in February as released by FINRA. Its up 176.67% from 3,000 shares previously. With 100 avg volume, 83 days are for Icc Holdings Incorporated (NASDAQ:ICCH)’s short sellers to cover ICCH’s short positions. The SI to Icc Holdings Incorporated’s float is 0.37%. The stock decreased 3.82% or $0.6 during the last trading session, reaching $15.11. About 5,817 shares traded or 413.87% up from the average. ICC Holdings, Inc. (NASDAQ:ICCH) has 0.00% since February 6, 2017 and is . It has underperformed by 16.70% the S&P500.




ICC Holdings, Inc., through its subsidiary, Illinois Casualty Company, provides property and casualty insurance products to the food and beverage industry in the United States. The company has market cap of $47.82 million. The firm offers commercial multi-peril, liquor liability, workersÂ’ compensation, and umbrella liability insurance products. It has a 32.15 P/E ratio. It also rents real estate properties.

Among 6 analysts covering Entellus Medical (NASDAQ:ENTL), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Entellus Medical had 9 analyst reports since August 9, 2015 according to SRatingsIntel. William Blair downgraded the shares of ENTL in report on Friday, December 8 to “Hold” rating. The company was initiated on Tuesday, June 14 by BTIG Research. Piper Jaffray maintained Entellus Medical, Inc. (NASDAQ:ENTL) rating on Monday, August 21. Piper Jaffray has “Buy” rating and $21.0 target. The firm earned “Hold” rating on Monday, October 16 by Canaccord Genuity. As per Thursday, October 6, the company rating was initiated by Deutsche Bank. On Sunday, August 9 the stock rating was maintained by Canaccord Genuity with “Buy”. The stock of Entellus Medical, Inc. (NASDAQ:ENTL) earned “” rating by Piper Jaffray on Tuesday, September 29.

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company has market cap of $617.22 million. The firm offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It currently has negative earnings. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use tool that provides real-time trans-illumination of the sinus cavity; Light Seeker, a tool with optical fibers embedded into the device to allow ear, nose, and throat physicians to access the frontal sinus and trans-illuminate the sinus cavity; Maxillary Seeker, a tool that allow users to find the correct angle to access the natural maxillary ostia; and Sphenoid Seeker/Freer, a two-in-one tool that enables ENT physicians to navigate access to the sphenoid ostium.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.